Discussion Paper to Explore Managing Validation Activities of CMOs
This article was originally published in The Gold Sheet
Executive Summary
Pharmaceutical manufacturers need to carefully plot out how they are going to manage the validation activities with their manufacturing partners. Not planning out these activities before the knowledge transfer can raise the ire of FDA.
You may also be interested in...
ISPE Talks Process Validation: Managing CMOs, Figuring PPQ Batches
The pharmaceutical industry is proposing new approaches for managing validation activities of contract manufacturing organizations and for estimating the number of batches to run during process validation.
FDA Guidance Exempts Legacy Products from Early Stage Process Validation; Endorses Use of PAT
FDA’s final process validation guidance clarifies that legacy products, or products that are currently on the market, will be exempt from early stage process validation. The guidance also endorses the use of process analytical technology for monitoring product quality.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”